Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Breast Cancer Awareness Month: raising awareness with inspirational patient stories

10/14/2020 | 10:35am EST

By Steven Hildemann, MD, PhD, EVP, Chiel Medical Officer

The facts and figures around breast cancer bring into focus the importance of raising awareness of the true scale of this globally prevalent disease. Breast cancer is the most common cancer in women1. It comprises of 24% of all cancers diagnosed in women2 with one in eight women diagnosed with breast cancer in their lifetime3, with up to 6% of women diagnosed before the age of 404. However, each of these statistics represents an individual woman living with this disease.

By actively listening to patients and working with organizations like Europa Donna, at Ipsen we know that women living with breast cancer need holistic support that goes beyond their treatment. Advice on nutrition, wellness, fertility and disease management along with interviews with healthcare professionals and stories from other patients can prove valuable resources. This is the support we are aiming to provide through platforms such as Everyday Wins, a program co-created with Europa Donna.

For this year's breast cancer awareness month, we are amplifying Everyday Wins patient stories to the program in the hope of providing a source of inspiration and support to those who are living with breast cancer. Each of the women featured in these videos have managed their disease in a personal way, having been diagnosed at various stages of their lives between the ages of 31 and 42. They each speak to common themes of continuing to pursue their life plans and a drive to help others who may be going through a similar experience. From raising awareness in local schools, founding patient associations, creating support groups through social media or just putting a smile on someone's face, each of these women tells the story of resilience. As a practicing lecturer, clinician and Ipsen's Chief Medical Officer, I see how improved outcomes can be achieved when patients do not allow their lives to be defined by a disease such as breast cancer5. That's why raising awareness and sharing inspirational stories to an audience of all ages is key.

At Ipsen, we strive to make measurable improvements to patients' lives. We are working with nearly 200 patient organizations to listen to patients and understand their personal journeys beyond statistics. Then, we translate their voice into insights and co-create initiatives that draw on their needs for support.

Putting patients at the heart of everything we do is also a belief that resonates with me personally. Alongside my career in the biopharmaceutical sector, I have continued to see patients and teach in academic centers. Being in touch with what matters to patients and their families gives us all at Ipsen the energy and inspiration for the work we deliver in the industry every day.

[1] www.who.int/cancer/detection/breastcancer/en/ [Last accessed October 2020]

[2] https://www.wcrf.org/dietandcancer/breast-cancer [Last accessed October 2020]

[3] www.breastcancercare.org.uk/information-support/have-i-got-breast-cancer/what-breast-cancer [Last accessed October 2020]

[4] DeSantis CE and al. Breast cancer statistics, 2019: CA Cancer J Clin.69:438-451; 2019

[5] Zhi Xuan Ng, Mei Shan Ong, Tamilarasi Jegadeesan, et al. Breast Cancer: Exploring the Facts and Holistic Needs during and beyond Treatment: Healthcare 2017, 5(2), 26; 10.3390/healthcare5020026

Disclaimer

Ipsen SA published this content on 14 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 October 2020 14:34:04 UTC


© Publicnow 2020
All news about IPSEN
12/01IPSEN : receives FDA Fast Track designation for investigational irinotecan lipos..
AQ
12/01France's Ipsen plans $3.6 billion investment in drugs pipeline
RE
12/01IPSEN : new strategic priorities unveiled at virtual Capital Markets Day event
PU
12/01IPSEN : Highlights New Strategic Priorities and Provides Mid-Term Financial Outl..
BU
11/30IPSEN : receives FDA Fast Track designation for investigational irinotecan lipos..
PU
11/25EACD 2020 : How the use of functional assessments in clinical trials provides me..
PU
11/18ALERT : New purchases in the Investor Europe portfolio
10/27IPSEN : Disclosure of Transactions in Own Shares Between 10/19/2020 And 10/20/20..
BU
10/23IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
AQ
10/22IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
More news
Financials
Sales 2020 2 636 M 3 204 M 3 204 M
Net income 2020 451 M 548 M 548 M
Net Debt 2020 749 M 911 M 911 M
P/E ratio 2020 12,9x
Yield 2020 1,49%
Capitalization 5 741 M 6 975 M 6 977 M
EV / Sales 2020 2,46x
EV / Sales 2021 2,15x
Nbr of Employees 5 807
Free-Float 42,0%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 94,83 €
Last Close Price 69,50 €
Spread / Highest target 62,6%
Spread / Average Target 36,5%
Spread / Lowest Target 16,5%
EPS Revisions
Managers
NameTitle
David G. Loew Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN-12.03%6 975
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033